Direct-acting antivirals can reactivate HBV, drug regulator advises

DOCTORS are being urged to screen hepatitis C patients for current or previous hepatitis B infection before beginning them on direct-acting antivirals (DAA).

A data review shows the drugs have been associated with reactivation of HBV in a small number of patients, the TGA says in a new safety advisory, following a similar advisory from the US drug authority in October.